360 related articles for article (PubMed ID: 31229160)
21. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
[TBL] [Abstract][Full Text] [Related]
22. B-cell Non-Hodgkin Lymphomas with Plasmacytic Differentiation.
Harmon CM; Smith LB
Surg Pathol Clin; 2016 Mar; 9(1):11-28. PubMed ID: 26940265
[TBL] [Abstract][Full Text] [Related]
23. Study of the Utility of Myeloid Cell Nuclear Differentiation Antigen (MNDA) in the Diagnosis of Marginal Zone Lymphoma.
Gupta N; Roychoudry S; Sticco KL; Hsu P; Zhang X; Sheikh-Fayyaz S
Appl Immunohistochem Mol Morphol; 2023 Apr; 31(4):217-223. PubMed ID: 36867739
[TBL] [Abstract][Full Text] [Related]
24. Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Chakraborty R; Kapoor P; Ansell SM; Gertz MA
Expert Rev Anticancer Ther; 2015; 15(10):1143-56. PubMed ID: 26196236
[TBL] [Abstract][Full Text] [Related]
25. Results of Upfront Therapy for Marginal Zone Lymphoma.
Ortega JL; Cabanillas F; Rivera N; Tirado-Gomez M; Hallman D; Pardo WI; Bruno M
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):879-883. PubMed ID: 29042174
[TBL] [Abstract][Full Text] [Related]
26. Trends in incidence, therapy and outcome of localized nodal and extranodal marginal zone lymphomas: declining incidence and inferior outcome for gastrointestinal sites.
Kuper-Hommel MJ; van de Schans SA; Vreugdenhil G; van Krieken JH; Coebergh JW
Leuk Lymphoma; 2013 Sep; 54(9):1891-7. PubMed ID: 23302044
[TBL] [Abstract][Full Text] [Related]
27. Marginal Zone Lymphoma: State-of-the-Art Treatment.
Sindel A; Al-Juhaishi T; Yazbeck V
Curr Treat Options Oncol; 2019 Dec; 20(12):90. PubMed ID: 31807935
[TBL] [Abstract][Full Text] [Related]
28. Significances of MYD88
Meng Q; Cao XX; Li J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):578-582. PubMed ID: 28877839
[TBL] [Abstract][Full Text] [Related]
29. Detection of MYD88 L265P mutations in formalin-fixed and decalcified BM biopsies from patients with lymphoplasmacytic lymphoma.
Capaldi IB; May AM; Schmitt-Graeff A; Follo M; Aumann K; Kayser G; Perazzo JC; Werner M; Fisch P
Exp Mol Pathol; 2014 Aug; 97(1):57-65. PubMed ID: 24842316
[TBL] [Abstract][Full Text] [Related]
30. Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Burnworth B; Wang Z; Singleton TP; Bennington A; Fritschle W; Bennington R; Brodersen LE; Wells DA; Loken MR; Zehentner BK
Leuk Res; 2016 Dec; 51():41-48. PubMed ID: 27890075
[TBL] [Abstract][Full Text] [Related]
31. [The pathology and genetic background of lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia].
Timár B
Magy Onkol; 2017 Mar; 61(1):6-11. PubMed ID: 28273183
[TBL] [Abstract][Full Text] [Related]
32. VS38 staining contributes to a novel gating strategy in flow cytometry for small B cell lymphoma, especially in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.
Mizuta S; Yamane N; Mononobe S; Watanabe A; Matsuki S; Komai T; Koba Y; Mitani S; Kawata T; Tamekane A; Watanabe M
Cytometry B Clin Cytom; 2022 Jan; 102(1):50-61. PubMed ID: 33682304
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic features of Waldenstrom's macroglobulinemia and marginal zone lymphoma: are they distinct or the same entity?
Berger F; Traverse-Glehen A; Felman P; Callet-Bauchu E; Baseggio L; Gazzo S; Thieblemont C; Ffrench M; Magaud JP; Salles G; Coiffer B
Clin Lymphoma; 2005 Mar; 5(4):220-4. PubMed ID: 15794852
[TBL] [Abstract][Full Text] [Related]
34. Contemporary management of nodal and primary splenic marginal zone lymphoma.
Leslie LA; Feldman TA; McNeill A; Timberg M; Iida H; Goy AH
Expert Rev Hematol; 2019 Dec; 12(12):1011-1022. PubMed ID: 31619091
[No Abstract] [Full Text] [Related]
35. Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.
Xu L; Hunter ZR; Tsakmaklis N; Cao Y; Yang G; Chen J; Liu X; Kanan S; Castillo JJ; Tai YT; Zehnder JL; Brown JR; Carrasco RD; Advani R; Sabile JM; Argyropoulos K; Lia Palomba M; Morra E; Trojani A; Greco A; Tedeschi A; Varettoni M; Arcaini L; Munshi NM; Anderson KC; Treon SP
Br J Haematol; 2016 Mar; 172(5):735-44. PubMed ID: 26659815
[TBL] [Abstract][Full Text] [Related]
36. Myeloid cell nuclear differentiation antigen is expressed in a subset of marginal zone lymphomas and is useful in the differential diagnosis with follicular lymphoma.
Metcalf RA; Monabati A; Vyas M; Roncador G; Gualco G; Bacchi CE; Younes SF; Natkunam Y; Freud AG
Hum Pathol; 2014 Aug; 45(8):1730-6. PubMed ID: 24925224
[TBL] [Abstract][Full Text] [Related]
37. Nodal marginal zone B-cell lymphoma: a diagnostic and therapeutic dilemma.
Traverse-Glehen A; Bertoni F; Thieblemont C; Zucca E; Coiffier B; Berger F; Salles G
Oncology (Williston Park); 2012 Jan; 26(1):92-9, 103-4. PubMed ID: 22393802
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical Expression of Lymphoid Enhancer Binding Factor 1 in CD5-Positive Marginal Zone, Lymphoplasmacytic, and Follicular Lymphomas.
Patel N; Durkin L; Bodo J; Hsi ED
Am J Clin Pathol; 2020 Apr; 153(5):646-655. PubMed ID: 31953940
[TBL] [Abstract][Full Text] [Related]
39. Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic review.
van den Brand M; van Krieken JH
Haematologica; 2013 Jul; 98(7):1003-13. PubMed ID: 23813646
[TBL] [Abstract][Full Text] [Related]
40. Nodal marginal zone lymphoma: Clinical features, diagnosis, management and treatment.
Tadmor T; Polliack A
Best Pract Res Clin Haematol; 2017; 30(1-2):92-98. PubMed ID: 28288722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]